title: Bone-Targeted Therapy.
abstract: Bisphosphonates and denosumab are well established components of the therapy for osteoporosis and osseous metastases. Their relevance in the adjuvant situation for breast cancer patients is being discussed in part controversially due to the heterogeneous nature of the available data. In particular, it appears that post-menopausal women benefit from an adjuvant therapy with bisphosphonates. In the present contribution we discuss the clinical relevance of osteoprotective therapy in the metastatic and adjuvant settings. Above all the current AGO guidelines on osteo-oncology and bone health have been taken into consideration for recommendations to implement the available data.
authors.affiliation: Universitätsfrauenklinik Düsseldorf, Heinrich-Heine Universität Düsseldorf, Düsseldorf.
authors.forename: J
authors.initials: J
authors.lastname: Salmen
authors.affiliation: Frauenklinik, Kath. Marienkrankenhaus Hamburg, Hamburg.
authors.forename: M
authors.initials: M
authors.lastname: Banys-Paluchowski
authors.affiliation: Universitätsfrauenklinik Düsseldorf, Heinrich-Heine Universität Düsseldorf, Düsseldorf.
authors.forename: T
authors.initials: T
authors.lastname: Fehm
keywords: adjuvant therapy; bisphosphonates; bone metastases; breast cancer; denosumab; osteoporosis